nanoliposomal irinotecan
ipsen,takeda,servier
['net-02']
dr. mcnamara presents net-02, nal-iri/5-fu vs docetaxel for 2l nec. 6-month pfs met (primary endpoint) in nal-iri/5-fu arm, not docetaxel arm. #asco22 
Gastrointestinal medical oncology, cancer of unknown primary, and value-based cancer care delivery. Tweets mine.